Poolbeg Pharma (POLB.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $75M

Market Cap: $43.0MFounded: 2021HQ: London, United Kingdom

Sector Ranking#313 in Small Molecule Drugs

Overview

Poolbeg Pharma is a UK-based, AIM-listed biotech founded in 2021 with a mission to develop high-value therapies for large markets with unmet needs. Its strategy centers on a capital-efficient model of de-risking assets through early clinical development before pursuing partnerships. Key achievements include securing FDA Orphan Drug Designation for its lead oncology asset, POLB 001, and building a proprietary AI discovery platform powered by unique human challenge trial data. The company aims to accelerate pipeline growth while minimizing substantial capital expenditure.

Oncology Supportive CareMetabolic Disease (Obesity)Infectious Disease

Technology Platform

An AI-led drug discovery platform powered by a proprietary, multi-omics dataset from over 20 years of human challenge trials, used to identify novel drug targets and repurpose opportunities in immunology and infectious disease.

Funding History

2

Total raised:$75M

Series A$50MRTW InvestmentsMar 15, 2022

Seed$25MRTW InvestmentsJul 15, 2021

Opportunities

Poolbeg's lead asset, POLB 001, addresses a critical bottleneck in the rapidly expanding cancer immunotherapy market, with a potential to unlock >$10B in value by enabling safer, broader treatment access.

Its oral GLP-1 program taps into the massive, growing obesity market with a highly sought-after patient-friendly formulation, representing a major partnership opportunity.

Risk Factors

The company faces high clinical risk with its lead program's upcoming Phase 1b/2 readout, and as a pre-revenue AIM-listed biotech, it is exposed to financing and liquidity risks dependent on capital markets.

Intense competition in both the obesity and AI drug discovery landscapes presents significant commercial and technological challenges.

Competitive Landscape

For POLB 001, competition is nascent with no approved preventative therapies, positioning it as a potential first-in-class agent. In obesity, it faces giants like Novo Nordisk and Eli Lilly, competing on the basis of oral convenience. Its AI platform competes in a crowded field but is differentiated by its unique, proprietary human challenge trial dataset.